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A B S T R A CT  
The coronavirus strain, SARS-CoV-2 causative agent of the pandemic viral pneumonia disease 
COVID-19, identified in the late 2019. Unfortunately, there is no vaccine or therapeutics available to 
control the disease. Although, earlier research efforts of SARS pandemic (2003) provides the precious 
information to the researchers for fast track vaccine development. Research efforts for vaccine 
development of COVID-19 pandemic are unprecedented in terms of promising time period. The 
inactivated whole virus-based SARS-CoV-2 vaccine is first one developed and entered into clinical trial. 
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However, later on after announce of complete genome sequence of SARS-CoV-2, vaccine based on 
recombinant viral vector, nucleic acid and immunogenic fragment also introduced. Previous experience 
of undesired immunopotentiation in SARS-CoV studies represents, vaccine safety should be the main 
concern.  Researchers believe that next generation vaccine approaches using recombinant technology 
such as viral vector or subunit protein-based vaccine will be more effective and safer. This review 
describes brief information of the major vaccine candidates and the current scenario of vaccine 
approaches against COVID-19 pandemic. 
 
Keywords: COVID-19, Vaccine, SARS-CoV-2  
1 Introduction 
The pandemic COVID-19 disease caused by severe acute respiratory syndrome corona virus-2 (SARS-
CoV-2) started in December 2019 from Wuhan, China, later on within few months this infectious disease 
spread in all over the world [1]. SARS-CoV-2 belongs to the family coronavirdae in the genus 
betacoronavirus. It poses positive-sense single-stranded RNA genome, approximately 29,903 bp 
nucleotides long [2], including four major structural proteins, viz., spike (S), membrane (M), envelope (E) 
and nucleocapsid (N), sixteen non-structural proteins (nsp1-16) and five to eight accessory proteins [3]. 
High predominance and wide distribution of coronaviruses influence the genetic diversity and frequent 
recombination in genome, increase the risk of pandemic situation [2, 4]. Coronaviruses is constitute of the 
subfamily Orthocoronavirinae, and classified into four genera including alpha, beta, gamma and delta [5]. 
Infectious disease caused by corona viruses have been identified in several avian hosts as well as in various 
mammals, including camels, bats, masked palm civets, mice, dogs, and cats [6]. Total seven human 
coronaviruses have been identified till date, including the new pandemic SARS-CoV-2, which is close 
similar to human severe acute respiratory syndrome corona virus (SARS-CoV), a species of coronavirus 
which infects humans, bats, and camels [7]. SARS-CoV, first identified in the year 2003, which causes severe 
acute respiratory syndrome (SARS) and shows unique pathogenesis as respiratory tract infections [8]. 
Human SARS-CoV is believed to be originate from animal as evidenced >99% nucleotide homology with 
SARS-CoV–like virus, recovered from palm civets or other animals of china meat market [9]. Symptoms as 
common cold and headache with mild illness have been reported in human corona virus infection. 
Although, infections of SARS, MERS, and COVID-19 have been reported to the most life-threatening 
disease, infected person may have severe symptoms like pneumonia and acute respiratory distress syndrome 
[10].  
Presently COVID-19 is terrific for the world and precipitously transmission of virus from infected 
individuals or from aerosol droplets has been reported earlier [11]. Asymptomatic nature of virus and 
human to human transfer by sneezing droplets makes the situation terrific that results spread of the disease 
worldwide. Typical clinical symptoms of disease are dry cough, fever, breathing difficulties and pneumonia 
[12, 13]. In last two decades, acute viral respiratory disease following by pandemic SARS-CoV (2003) and 
MERS-CoV (2012) causes illness and death of the individuals due to weak immune system or respiratory 
tract infection [14]. Present scenario of COVID-19 shows situation is pandemic; globally more than 60, 
57,853 confirmed cases including 3, 71,166 deaths have been reported to WHO since December 2019 to 
2nd JUN 2020. Pandemic situation caused the travel restriction and nation wise lock down in many countries 
that also cause economic loss internationally [15]. Vaccine development is only the way to restrict the 
pandemic situation; an effective vaccine strategy is required that induce the cell-mediated immunity and 
deliver the antibody responses against SARS-CoV-2 in vaccinated host. Presently no approved cure is 
available for SARS-CoV-2; although, scientists from all over the world are giving their best efforts to 
develop protective vaccine or therapeutics. As per the newsletter of Coalition for Epidemic Preparedness 
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Innovations (CEPI) at least 115 vaccine projects are in progress. However, 78 projects reported as actively 
running, in which many are in preclinical stage and some of these have been entered into clinical stage [17]. 
2 Vaccine Approaches 
Development of effective vaccine to prevent infection of SARS-CoV-2 is urgently required, as the world is 
becoming victim of the pandemic COVID-19. There are many strategies are use as routine method of 
vaccine development for virus diseases such as live-attenuated vaccine, inactivated whole virus vaccine, 
recombinant viral vector based vaccine, nucleic acid based vaccine and immunogenic fragment based 
vaccine [18]. The present economic impact and human life threat due to the COVID-19 is forcing to the 
researchers for moving towards the next-generation vaccine approaches, that are usually based on genomics 
and structural biology. Many of these approaches are not currently allowed as licensed vaccine. Although, 
experience of success in case of malaria vaccine e.g. RTS,S/AS01 and HIV vaccine encourages researchers 
to exploit the opportunities for next-generation vaccine approaches that support to early development 
platforms [19,  20]. Complete genome sequence of SARS-CoV-2 shares 79.6% and 96.2% nucleotide 
sequence identity with SARS-CoV and RaTG13 bat coronavirus, respectively [21]. Numerous nucleotide 
sequence based study also indicates that the bat might be a probable origin of SARS-CoV-2 [22, 23]. 
Nucleotide sequence study of surface glycoprotein spike (S) revealed ∼72% nucleotide sequence similarity 
between SARS-CoV-2 and SARS-CoV [24, 25]. It also has been confirmed that S protein of SARS-CoV-2 
attach on host cell by angiotensin converting enzyme-2 (ACE2), the same cell entry receptor used by SARS-
CoV, to spread the disease [26]. Research studies in last two decades done for vaccine development of 
SARS allows researcher to use already shaped groundwork of vaccine strategy, on the basis of SARS 
genome identity with COVID-19 [27]. Although, a new vaccine will require careful safety evaluations for 
immunopotentiation that may found in the form of increased infectivity or eosinophilic infiltration, which 
occur after immunizations with whole virus vaccines or recombinant vaccines [28]. In India, seven different 
industries (Zydus Cadila, Serum Institute of India, Biological E, Bharat Biotech, Indian Immunologicals, 
Mynvax and Hester Biosciences) are in race to develop a better vaccine candidate with support from the 
government organizations and academic institutions, researchers are working on 14 vaccine candidates on 
different levels [29].  However, more than 100 companies from all over the world are also working on 
different projects, in which mostly are in preclinical evaluation stage and ten in clinical evaluation stage as 
per the report of WHO and CEPI, 2 Jun 2020 [16]. Scientists are using specific significance platform for 
early development of an effective vaccine e.g. whole virus inactivated and live attenuated vaccine, Nucleic 
acid (DNA, RNA) vaccine and viral vector based recombinant vaccine. A brief of these strategies is 
described here and vaccines that are presently in clinical evaluation listed in table-1. 
2.1 Whole-Virus live and Inactivated Vaccines  
Purified virus is grown on tissue culture and inactivates by heat or chemically after harvest, a traditionally 
classical method of inactivated vaccine development. There are several advantages of inactivated vaccine 
such as; it does not need any genetic manipulation, cost effective and good safety profile [30]. However, it 
requires live virus culture that generates the risk of high-level containment. Safety and efficacy of inactivated 
COVID-19 vaccine have been confirmed by multinational companies in animal model [17]. Vaccine 
candidate PicoVacc has been reported earlier for partial and complete protection against SARS-CoV-2 in 
macaques following by testing neutralizing antibodies protection in ten representative strain of SARS-CoV-
2 [31]. In response to the outbreak of SARS-CoV2, University of hong kong have developed a vaccine 
candidate based on the live attenuated influenza virus platform, they adapted it to express the surface 
protein of SARS-CoV-2, this vaccine will be consider as flu-based vaccine and can combine with any 
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seasonal flu vaccine strains [32]. A “codon deoptimization” technology to attenuate viruses has developed 
by Codagenix and the same strategy is using for exploring COVID-19 vaccine [33]. Inactivated vaccine 
developed by Wuhan Institute of Biological Products/Sinopharm, Beijing Institute of Biological 
Products/Sinopharm and Sinovac are presently in clinical evaluation trial phase-1. 
Table 1: COVID-19 vaccine development programs under clinical evaluation [16] 
Vaccine type  Candidate type  Developer Current stage of 
clinical evaluation 
Non-
Replicating 
Viral Vector 
ChAdOx1-S 
 
 
 
Adenovirus Type 
5  
Vector 
 
University of 
Oxford/AstraZeneca 
 
 
CanSino Biological 
Inc./Beijing Institute 
of Biotechnology 
 
Phase2b/3 
 
 
 
Phase 2 
 
 
RNA 
 
LNP-encapsulated 
mRNA 
 
3 LNP-mRNAs 
 
Moderna/NIAID 
 
 
BioNTech/Fosun 
Pharma/Pfizer 
 
Phase 2 
 
 
Phase 1/2 
 
DNA 
 
DNA plasmid 
vaccine with 
electroporation 
 
Inovio 
Pharmaceuticals 
 
Phase 1 
 
 
Inactivated 
 
Inactivated 
 
 
 
Inactivated 
 
 
 
Inactivated 
 
 
 
 
Inactivated + alum 
 
Beijing Institute of 
Biological 
Products/Sinopharm 
 
Wuhan Institute of 
Biological 
Products/Sinopharm 
 
Institute of Medical 
Biology , Chinese 
Academy of Medical 
Sciences 
 
Sinovac 
 
Phase 1/2 
 
 
 
Phase 1/2 
 
 
 
Phase 1 
 
 
 
 
Phase 1/2 
 
 
Protein 
Subunit 
 
Full length 
recombinant 
SARS CoV-2 
glycoprotein 
nanoparticle 
vaccine adjuvanted 
with Matrix M 
 
Novavax 
 
Phase 1/2 
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2.2 Nucleic acid vaccines  
Nucleic acid vaccine is a major concern for licensing, till now there is no nucleic acid based vaccine is 
licensed for human. Pandemic situation needs fast track vaccine development, and nucleic acid platforms 
may be a solution for the same. The Innovation and Value Initiative (IVI), created a DNA-based vaccine 
candidate (INO-4800) targeting SARS-CoV-2 S protein, recently they demonstrated that vaccination with 
INO-4800 generates robust neutralizing antibodies and T cell responses against SARS-CoV-2 in mice and 
guinea pigs [34]. Moderna/NIH and CureVac are working on development of mRNA vaccine, and clinical 
trial of Moderna’s candidate vaccine mRNA-1273 has been performed earlier [35]. Another vaccine 
candidate BNT162 developed by BioNTech, Fosun Pharma and Pfizer is also in clinical trial phase 1/2 
(ClinicalTrials.gov Identifier: NCT04368728) to determine the safety, immunogenicity and optimal dose 
level [36]. 
2.3 Subunit vaccines 
Immunogenic studies of MERS and SARS represented the S protein and its fragments, S1, S2, RBD, and 
N protein, are major targets for developing vaccines. So it is expected for COVID-19 vaccines, the similar 
regions of SARS-CoV-2 could also be considered as key targets for effective vaccine development [37, 38]. 
However, global production capacity might be limited and integrity of antigen or epitope also needs to 
confirm. Subunit vaccines elicit an immune response against the S-spike protein and prevent its docking 
with the host ACE2 receptor [39]. Previous research studies have been demonstrated the subunit vaccines 
based on recombinant S or S1 protein found effective in case of SARS-CoV and MERS-CoV [40]. Clover 
Biopharmaceuticals is developing a subunit vaccine consisted trimerized SARS-CoV-2 S-protein by using 
their patented Trimer-Tag technology [41]. The receptor-binding domain (RBD) was identified earlier in 
SARS-CoV-2 S protein and suggested that S1 subunit consists of the RBD, which mediates virus entry into 
host cells through ACE2 receptor [42, 43]. The significance of RBD provides the rationale for choosing 
RBD as a prime target for subunit vaccine. In case of early SARS coronavirus vaccine research, undesired 
immunopotentiation is a major issue reported in whole virus or complete S protein based vaccines [28]. 
RBD-based vaccine also provides an advantage to minimize the host immunopotentiation. An 
Immunogenic vaccine candidate, virus-like nanoparticles based on SARS-CoV-2 S-protein recombinant 
expression developed by Novavax and the construct is in clinical trial phase-1 [44]. Industries and academic 
organizations such as expresS2ion, iBio, Novavax, AdaptVac, Biological E Ltd, Baylor College of Medicine, 
University of Queensland, and Sichuan Clover Biopharmaceuticals are also in preclinical phase [17]. The 
long-term protective immunity and presence of induced neutralizing antibodies reported, when SARS-CoV 
RBD proteins administrated in animal models [45]. Thus, S1 subunit targeted antibodies against SARS-
CoV-2 would be effective to provide protection and treatment of COVID-19. 
2.4 Vaccines based on viral vector (replicating and non-replicating) 
Recombinant viral vectors based vaccines have prospective for therapeutic use; they facilitate intracellular 
antigen expression and enhance immunogenicity without an adjuvant following by induced cytotoxic T 
lymphocyte (CTL) response [46]. MERS-CoV S glycoprotein expressed in Ankara and adenoviruses based 
recombinant vectors and demonstrated immunogenicity in mice [47]. Thus, viral vectors provide a 
promising tool for protective vaccine strategy. The first COVID-19 vaccine candidate based on adenovirus 
vector developed by Chen Wei group and human clinical testing on 16 March 2020 (ClinicalTrials.gov 
Identifier: NCT04313127). Recombinant adenovirus vaccine candidate, Ad5-nCoV developed by Cansino 
Biologics Inc. / Beijing Institute of Biotechnology, the recent clinical trial phase-2 of the same demonstrates 
that a single dose Ad5-nCoV vaccine produces virus-specific antibodies and T cells in 14 days [46]. Vaccine 
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candidates based on lentivirus vector namely, COVID-19/aAPC and LVSMENP- DC also have been 
developed by Shenzhen Geno-Immune Medical Institute and clinical trial for the same is in progress 
(ClinicalTrials.gov Identifier: NCT04276896; NCT04299724). 
3 Conclusion 
Scientist, doctors, medical staff and other social activist organization from all over the world are involved 
as frontline corona warriors against COVID-19. Although, successful research on different vaccine 
approaches are in progress for eliminate the pandemic situation. Hard work and efforts done in the last two 
decades for coronavirus strains such as SARS and MERS provide knowledge and ideas for effective vaccine 
development. Vaccine candidates, including inactivated whole-viruses, live viruses, recombinant protein 
subunits, and nucleic acids may offer better protection against pandemic COVID-19. However, research 
studies of coronaviruses demonstrate that vaccine based on subunit protein will be more effective than 
other candidates. Vaccine approaches currently in progress have their advantages and disadvantages. 
Consequently, it is the priority that vaccine prepared by any of the promising approach will require a 
carefully evaluation for safety and efficacy. The data presented in this review provides a judicious summary 
on efforts to develop a vaccine for the SARS-CoV-2. 
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